It has been found that miR-4429 can reduce the m6A-induced stability of Sec. 62 by targeting the METTL3 binding site, thereby preventing the progression of GC and providing innovative ideas for the targeted molecular therapy of GC [41]. Here, METTL3 is linked to gastric cancer.